Curi Bio Acquires South Korea-based Quvit Bio

BioIVT Acquires ZenBio

August 21, 2024

Healthcare Services

BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.

Curi (Curi Capital) Acquires RMB Capital to Form Curi RMB Capital

January 2, 2024

Wealth Management

Curi completed its previously announced acquisition of RMB Capital and merged Curi Capital with RMB to form Curi RMB Capital, a registered investment advisory firm with more than $11.3 billion in assets under advisement. The combined firm is headquartered in Chicago, retains leadership from both organizations, and has approximately 180 employees while positioning itself for expanded geographic reach and long-term growth.

Quanterix Corporation Acquires Akoya Biosciences

July 8, 2025

Medical Devices

Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.

Mitratech Acquires Quovant

January 19, 2022

Software

Mitratech, a provider of legal and compliance software, has acquired Quovant, a spend management and legal bill review provider that offers advanced analytics and AI-driven categorization. The acquisition adds Quovant's spend visibility, expert review services and analytics capabilities to Mitratech's suite, enhancing legal spend management for large corporate and healthcare customers.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.